The association between body mass index and efficacy of pembrolizumab as second‐line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

The association between body mass index and efficacy of pembrolizumab as second‐line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma

Published:2022-08-17 Issue:3 Volume:12 Page:2702-2712
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Zhang Xinyi¹²,Rui Mengyu²³,Lin Chao¹,Li Zhi¹²,Wei Dongliang²³,Han Ruxue¹²,Ju Houyu²³,Ren Guoxin²³^ORCID

Affiliation:

1. School of Stomatology Weifang Medical University Weifang China

2. Department of Oral Maxillofacial‐Head and Neck Oncology Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China

3. National Clinical Research Center of Stomatology Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5152

Reference37 articles.

1. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

2. Immunotherapy for squamous cell carcinoma of the head and neck